BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 36532035)

  • 1. Immune landscape-based machine-learning-assisted subclassification, prognosis, and immunotherapy prediction for glioblastoma.
    Li H; He J; Li M; Li K; Pu X; Guo Y
    Front Immunol; 2022; 13():1027631. PubMed ID: 36532035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.
    Wang Z; Wang Y; Yang T; Xing H; Wang Y; Gao L; Guo X; Xing B; Wang Y; Ma W
    Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33839757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Analysis of the Tumor Immune Microenvironment Landscape in Glioblastoma Reveals Tumor Heterogeneity and Implications for Prognosis and Immunotherapy.
    Zhao R; Pan Z; Li B; Zhao S; Zhang S; Qi Y; Qiu J; Gao Z; Fan Y; Guo Q; Qiu W; Wang S; Wang Q; Zhang P; Guo X; Deng L; Xue H; Li G
    Front Immunol; 2022; 13():820673. PubMed ID: 35309323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune microenvironments differ in immune characteristics and outcome of glioblastoma multiforme.
    Zhang B; Shen R; Cheng S; Feng L
    Cancer Med; 2019 Jun; 8(6):2897-2907. PubMed ID: 31038851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating machine learning and bioinformatics analysis to m6A regulator-mediated methylation modification models for predicting glioblastoma patients' prognosis and immunotherapy response.
    Li C; Liu W; Liu C; Luo Q; Luo K; Wei C; Li X; Qin J; Zheng C; Lan C; Wei S; Tan R; Chen J; Chen Y; Huang H; Zhang G; Huang H; Wang X
    Aging (Albany NY); 2023 May; 15(10):4051-4070. PubMed ID: 37244287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PTEN-associated immune prognostic signature reveals the landscape of the tumor microenvironment in glioblastoma.
    Yu J; Lai M; Zhou Z; Zhou J; Hu Q; Li J; Li H; Chen L; Wen L; Zhou M; Cai L
    J Neuroimmunol; 2023 Mar; 376():578034. PubMed ID: 36791582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy.
    Cui X; Ma C; Vasudevaraja V; Serrano J; Tong J; Peng Y; Delorenzo M; Shen G; Frenster J; Morales RT; Qian W; Tsirigos A; Chi AS; Jain R; Kurz SC; Sulman EP; Placantonakis DG; Snuderl M; Chen W
    Elife; 2020 Sep; 9():. PubMed ID: 32909947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
    Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression.
    Meng Q; Zhang Y; Li G; Li Y; Xie H; Chen X
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):1881-1895. PubMed ID: 33693962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining single-cell sequencing and spatial transcriptome sequencing to identify exosome-related features of glioblastoma and constructing a prognostic model to identify BARD1 as a potential therapeutic target for GBM patients.
    Zhao S; Wang Q; Ni K; Zhang P; Liu Y; Xie J; Ji W; Cheng C; Zhou Q
    Front Immunol; 2023; 14():1263329. PubMed ID: 37727789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of Different Subtypes of Immune Cell Infiltration in Glioblastoma to Aid Immunotherapy.
    Feng P; Li Z; Li Y; Zhang Y; Miao X
    Front Immunol; 2022; 13():799509. PubMed ID: 35799789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Insights into Mesenchymal Signatures in Glioblastoma.
    Matsumoto Y; Ichikawa T; Kurozumi K; Date I
    Acta Med Okayama; 2022 Oct; 76(5):489-502. PubMed ID: 36352795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated multiomic analysis reveals disulfidptosis subtypes in glioblastoma: implications for immunotherapy, targeted therapy, and chemotherapy.
    Yang X; Cai Z; Wang C; Jiang C; Li J; Chen F; Li W
    Front Immunol; 2024; 15():1362543. PubMed ID: 38504986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of Genetic Determinants of Glioma Immune Phenotype by Integrative Immunogenomic Scale Analysis.
    Zhao B; Wang Y; Wang Y; Dai C; Wang Y; Ma W
    Front Immunol; 2021; 12():557994. PubMed ID: 34220791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immune cell landscape of glioblastoma patients highlights a myeloid-enriched and immune suppressed microenvironment compared to metastatic brain tumors.
    Musca B; Russo MG; Tushe A; Magri S; Battaggia G; Pinton L; Bonaudo C; Della Puppa A; Mandruzzato S
    Front Immunol; 2023; 14():1236824. PubMed ID: 37936683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a unique tumor cell subset employing myeloid transcriptional circuits to create an immunomodulatory microenvironment in glioblastoma.
    Yang K; Shi Y; Luo M; Mao M; Zhang X; Chen C; Liu Y; He Z; Liu Q; Wang W; Luo C; Yin W; Wang C; Niu Q; Zeng H; Bian XW; Ping YF
    Oncoimmunology; 2022; 11(1):2030020. PubMed ID: 35096487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Crosstalk between T Cells and Tumor Uncovers GBM-Specific T Cell Signatures in Blood: Noninvasive GBM Diagnosis Using Immunosensors.
    Dhinakaran AK; Dharmalingam P; Ganesh S; Venkatakrishnan K; Das S; Tan B
    ACS Nano; 2022 Sep; 16(9):14134-14148. PubMed ID: 36040842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and validation of neurotrophic factor-related gene signatures in glioblastoma and Parkinson's disease.
    Zhao S; Chi H; Yang Q; Chen S; Wu C; Lai G; Xu K; Su K; Luo H; Peng G; Xia Z; Cheng C; Lu P
    Front Immunol; 2023; 14():1090040. PubMed ID: 36825022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy development.
    Wu C; Qin C; Long W; Wang X; Xiao K; Liu Q
    J Big Data; 2022; 9(1):92. PubMed ID: 35855914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy.
    Desland FA; Hormigo A
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.